Day: September 28, 2018

Enrolling: Bateman-Horne InTime Drug Intervention Trial

The InTime Trial aims to assess the effects of the investigational drug, CT38, in terms of its safety and effectiveness in treating ME/CFS. There will be 18 people between 18 and 60 years of age enrolled in this study and participation will last up to approximately 4 months. Who: Dr. Lucinda Bateman, Located in Salt

Read More »
Scroll to Top